Coagadex market seen expanding through 2030 on rare bleeding disorder demand

The Coagadex market is projected to grow through 2030 as diagnosis rates rise, home infusion expands and access improves in emerging markets. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Coagadex is used to treat hemophilia B, a rare bleeding disorder tied to factor IX deficiency. - Market growth affects access to factor replacement therapy for patients who need ongoing bleeding control. - Rising diagnosis rates and broader treatment access could expand use of recombinant clotting factors over the next several years.

What happened: - The Business Research Company released a Coagadex market report in 2026 covering global market size, trends and forecasts for 2026-2035. - The report says the Coagadex market is gaining attention as hemophilia treatment advances and diagnostic methods improve. - A free sample of the report is available here. - The full report is available here.

The details: - Coagadex is a recombinant factor IX product that replaces the missing clotting protein in hemophilia B. - The therapy is typically given by intravenous injection. - The report links historical market growth to improved identification of factor IX deficiency, approval and availability of recombinant clotting factor therapies, growth of specialized hemophilia treatment centers, better bleeding management protocols and improved survival rates. - From 2026 to 2030, the report expects support from more rare bleeding disorder diagnoses, broader home infusion use, better reimbursement frameworks, wider access in emerging markets and continued recombinant innovation. - The report identifies growing use of recombinant clotting factors, more treatment options for rare bleeding disorders, a shift toward home-based hemophilia care, improved access to factor replacement therapy and preventive bleeding management as leading trends. - The report also says Coagadex addresses hereditary Factor X deficiency by replacing deficient clotting factors and helping manage bleeding episodes. - A December 2023 UK Haemophilia Centre Doctors’ Organisation report cited 6,835 patients with hemophilia A, 1,378 with hemophilia B, 1,845 carriers of hemophilia A, 892 females affected by factor VIII deficiency and 390 carriers of hemophilia B in the UK for 2023/24. - The report includes Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa in its global analysis. - The company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and key technology and future trend analysis.

Between the lines: - The report points to a market shaped less by one breakthrough drug and more by steady gains in diagnosis, care delivery and access. - North America’s lead suggests a mature treatment environment, while Asia-Pacific’s expected growth points to unmet need and expanding healthcare capacity. - Home-based care and reimbursement improvements could matter as much as clinical innovation for long-term market expansion.

What's next: - The report expects the strongest growth drivers through 2030 to come from better diagnosis, home infusion adoption and wider market access. - Asia-Pacific is expected to be the fastest-growing region in the forecast period. - The report says future growth will also depend on continued innovation in recombinant technology and broader adoption of preventive bleeding management.

The bottom line: - Coagadex’s market outlook is being driven by more diagnosed patients, more flexible care settings and broader global access, with North America still in front and Asia-Pacific poised to accelerate.